Nippon India Nifty Pharma ETF - Growth - Regular Plan

Other Plans and Options
  • (-1.31%)Nav, as on 20-05-2025

  • Previous Nav

  • Net Change on 20-05-2025

  • PersonalFN Rating

  • Category

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A
NIFTY PHARMA - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
SBI Nifty 50 ETF Jul 22, 2015 11.01 16.17 23.47 0.04 195,676.88
SBI BSE SENSEX ETF Mar 15, 2013 10.90 15.66 22.73 0.04 113,540.04
UTI Nifty 50 ETF Sep 01, 2015 11.01 16.17 23.48 0.05 61,103.05
UTI BSE Sensex ETF Sep 01, 2015 10.90 15.66 22.72 0.05 47,007.15
Nippon India ETF Nifty 50 BeES Dec 28, 2001 11.02 16.19 23.49 0.04 46,349.24

Fund Holdings as on 30-April-2025

  • Sun Pharmaceutical Industries Limited

  • Cipla Limited

  • Divi's Laboratories Limited

  • Dr. Reddy's Laboratories Limited

  • Lupin Limited

  • Torrent Pharmaceuticals Limited

  • Aurobindo Pharma Limited

  • Mankind Pharma Limited

  • Alkem Laboratories Limited

  • Laurus Labs Limited

  • Zydus Lifesciences Limited

  • Glenmark Pharmaceuticals Limited

  • IPCA Laboratories Limited

  • Abbott India Limited

  • Biocon Limited

  • JB Chemicals & Pharmaceuticals Limited

  • Ajanta Pharma Limited

  • Gland Pharma Limited

  • Natco Pharma Limited

  • Granules India Limited

  • Triparty Repo

  • Cash Margin - CCIL

  • Net Current Assets

View More

  • Pharmaceuticals & Drugs

  • Miscellaneous

View More

Fund Manager

  • Cash

  • Equity

View More

About Nippon India Nifty Pharma ETF

Scheme Analysis

Nippon India Nifty Pharma ETF is a ETFs - Index fund and belongs to Nippon India Mutual Fund. It was launched on 06-Jul-2021 and currently has an AUM of ₹887.84 crore. Nippon India Nifty Pharma ETF is benchmarked against NIFTY 50 - TRI as primary index and NIFTY PHARMA - TRI as secondary index.

The NAV of Nippon India Nifty Pharma ETF ended down ₹-0.29(-1.31%)yesterday to ₹21.899.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and

The Nippon India Nifty Pharma ETF is managed by Jitendra Tolani .

Fund House Contact

4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W) Mumbai - 400 013

022-68087000
022-68087097